טוען...
Patiromer and maintenance of RAASi therapy in hyperkalemic medicare patients
Background: Renin angiotensin aldosterone system inhibitor (RAASi) therapy is part of the cornerstone of therapy for patients (pts) with cardiovascular disease including hypertension, CHF, and/or CAD, but use is often limited by the development of hyperkalemia. Patiromer (PAT) is a sodium (Na)-free...
שמור ב:
| הוצא לאור ב: | J Drug Assess |
|---|---|
| Main Authors: | , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Taylor & Francis
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6764378/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21556660.2019.1658287 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|